Elzinga Kate E, Khan Omar F, Tang Andrew R, Fernandez Conrad V, Elzinga Christine L, Heng Daniel Yc, Vickers Michael M, Truong Tony H, Tang Patricia A
Department of Surgery, University of Alberta, Edmonton, AB, Canada.
Department of Internal Medicine, University of Calgary, Calgary, AB, Canada.
Clin Trials. 2016 Dec;13(6):574-581. doi: 10.1177/1740774516665597. Epub 2016 Aug 23.
The provision of study results to research participants is supported by pediatric and adult literature. This study assessed adult cancer patient preferences surrounding aggregate result disclosure to study participants.
A 46-item questionnaire was given to 250 adult cancer patients who had participated in oncology trials at a single center. Respondents answered questions surrounding their preferences for timing, content, and modality of communication for dissemination of study results.
Questionnaire completion rate was 76% (189/250). Most patients (92%) strongly felt a right to know study results. Patients preferred result dissemination via letter for trials with positive outcomes, but preferred in-person clinic visits for negative outcomes. Despite this, a majority of participants (59%) found letters acceptable to inform participants of negative results. Only a minority (36%) of the participants found Internet-based disclosure acceptable for negative trial results. Unfortunately, very few patients (8%) recalled having received the results for a study they participated in, and of these patients, less than half fully understood the results they were given.
Most clinical trial participants feel they have a right to study result disclosure, regardless of trial outcome. In-person visits are preferred for negative results, but more feasible alternatives such as letters were still acceptable for the majority of participants. However, Internet-based disclosure was not acceptable to most participants in oncology trials. Time and cost allocations for result disclosure should be considered during grant and ethics board applications, and clear guidelines are required to help researchers share the results with patients.
向研究参与者提供研究结果得到了儿科和成人文献的支持。本研究评估了成年癌症患者对于向研究参与者披露总体结果的偏好。
向在单一中心参加过肿瘤学试验的250名成年癌症患者发放了一份包含46个条目的问卷。受访者回答了有关他们对研究结果传播的时间、内容和沟通方式偏好的问题。
问卷完成率为76%(189/250)。大多数患者(92%)强烈认为自己有权了解研究结果。对于有积极结果的试验,患者更喜欢通过信件传播结果,但对于有消极结果的试验,患者更喜欢亲自到诊所就诊。尽管如此,大多数参与者(59%)认为信件可以用来告知参与者消极结果。只有少数参与者(36%)认为基于互联网的披露方式对于消极试验结果是可以接受的。不幸的是,很少有患者(8%)记得收到过他们参与研究的结果,在这些患者中,不到一半的人完全理解了他们得到的结果。
大多数临床试验参与者认为无论试验结果如何,他们都有权了解研究结果。对于消极结果,患者更喜欢亲自就诊,但对于大多数参与者来说,信件等更可行的替代方式仍然是可以接受的。然而,大多数肿瘤学试验参与者不接受基于互联网的披露方式。在申请资助和伦理委员会审批时,应考虑结果披露的时间和成本分配,并且需要明确的指导方针来帮助研究人员与患者分享结果。